Eris Lifesciences
- P/E
- 25.99
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 14.10%
- Debt to Equity
- 0.60
- EPS (TTM)
- ₹46.75
- Book Value
- ₹298.72
- Market Cap
- —
- P/E (TTM)
- 25.99
- P/B
- 4.07
- ROE
- 18.70%
- Dividend Yield
- 0.61%
- EBITDA
- ₹1,128 Cr
- 52W High
- ₹1,740.00
- 52W Low
- ₹1,069.00
- Day Range
- ₹1,178.20 – ₹1,220.10
- Volume
- 46,728
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Eris Lifesciences (this company) | ₹1,215.00 | 25.99 | ₹16,404 Cr | 4.07 | 0.61% | 18.70% | 14.10% | ₹3,230 Cr | ₹665 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.60% | 17.40% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 61
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 69
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 34
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 18
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 22
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
2- Stock is trading at 4.10 times its book value
- Tax rate seems low
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 4 | 7 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bullish
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 56.58
- Neutral
- MACD (12,26,9)
- −14.43
- Bullish
- SMA (50)
- 1,233.05
- Bearish
- SMA (200)
- 1,346.07
- Bearish
As of
Analyst Rating
10 of 11 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +18.02% |
|---|---|
| 5Y | +20.89% |
| 3Y | +22.91% |
| 1Y | +8.12% |
| TTM | +9.61% |
Net profit
| 10Y | +16.98% |
|---|---|
| 5Y | +12.79% |
| 3Y | +20.11% |
| 1Y | +72.80% |
| TTM | +62.20% |
Operating cash flow
| 10Y | +15.17% |
|---|---|
| 5Y | +7.49% |
| 3Y | +22.59% |
| 1Y | −49.48% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +6.98 pp |
|---|---|
| 5Y | +0.23 pp |
| 3Y | +3.80 pp |
| 1Y | +0.61 pp |
| TTM | −0.20 pp |
Revenue by year
| Mar 2017 | ₹750 Cr |
|---|---|
| Mar 2018 | ₹856 Cr |
| Mar 2019 | ₹982 Cr |
| Mar 2020 | ₹1,074 Cr |
| Mar 2021 | ₹1,212 Cr |
| Mar 2022 | ₹1,347 Cr |
| Mar 2023 | ₹1,685 Cr |
| Mar 2024 | ₹2,009 Cr |
| Mar 2025 | ₹2,894 Cr |
| Mar 2026 | ₹3,129 Cr |
Net profit by year
| Mar 2017 | ₹247 Cr |
|---|---|
| Mar 2018 | ₹295 Cr |
| Mar 2019 | ₹291 Cr |
| Mar 2020 | ₹297 Cr |
| Mar 2021 | ₹355 Cr |
| Mar 2022 | ₹406 Cr |
| Mar 2023 | ₹374 Cr |
| Mar 2024 | ₹397 Cr |
| Mar 2025 | ₹375 Cr |
| Mar 2026 | ₹648 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Eris Lifesciences trades at ₹1,177.7 as of 2026-11-03 with a market cap of ₹16,199 crore, a trailing PE of 25.19 and ROE of 16.62%. The stock sits 32% below its 52-week high of ₹1,740 despite delivering 69% TTM profit growth, while carrying a moderate debt-to-equity ratio of 0.60.
- TTM profit growth of 69% is exceptionally strong, indicating a sharp acceleration in earnings relative to the 5-year compounded profit growth of 12%
- Compounded sales growth of 23% over 3 years and 21% over 5 years reflects consistent above-market revenue expansion in the Indian pharma space
- 10-year compounded sales growth of 18% and profit growth of 17% demonstrate a long track record of sustained double-digit growth
- ROE has averaged 21% over 10 years and stood at 19% last year, indicating the business has historically generated healthy returns on shareholder capital
- Debt-to-equity of 0.60 is moderate for a pharmaceutical company that has been growing through acquisitions, suggesting leverage remains manageable
- The stock is trading at ₹1,177.7 which is roughly 10% above its 52-week low of ₹1,069, potentially reflecting a valuation reset after the correction from the ₹1,740 high
- ROCE of 15.72% indicates the company is generating reasonable returns on total capital employed even after accounting for debt
- Stock price CAGR of -27% over 1 year signals significant negative sentiment and underperformance despite strong underlying profit growth
- TTM sales growth has decelerated to 10% compared to the 3-year CAGR of 23%, raising questions about whether the high-growth phase in revenues is tapering
- The tax rate appears low, which may flatter reported earnings; any normalisation of tax rates could compress net profit margins
- PE of 25.19 against a TTM EPS of ₹46.75 prices in continued strong earnings delivery, and any miss could lead to further multiple contraction
- Dividend yield of just 0.62% offers minimal income return to shareholders, implying investors are entirely dependent on capital appreciation
- 3-year and 5-year stock CAGRs of 9% and 8% respectively have lagged the broader market indices over similar periods, suggesting the market has not fully rewarded the company's earnings growth
- Current ROE of 16.62% has declined from the 10-year average of 21%, potentially reflecting dilution of returns from acquisitions or rising equity base
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Limited recent news flow for Eris Lifesciences. The only development is the departure of COO Krishnakumar Vaidyanathan, which is a leadership change worth monitoring but not immediately alarming given the extended effective date of Sep 30, 2026. Investors should watch for a successor announcement and any operational impact in coming quarters.
- COO resigns from Eris Oct 5
Krishnakumar Vaidyanathan resigned as Executive Director and COO of Eris Lifesciences to pursue outside opportunities, effective Sep 30, 2026. The board accepted the resignation with a notice period waiver.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 | 892 |
| Expenses | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 | — |
| Operating Profit | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 | — |
| OPM % | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% | — |
| Other Income | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | −17 | 2 | 2 | — |
| Interest | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 | 46 |
| Depreciation | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 | 73 |
| PBT | 112 | 126 | 116 | 77 | 115 | 129 | 116 | 129 | 161 | 172 | 145 | 159 | 179 | 156 |
| Tax % | 17% | 3% | 12% | −4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | −75% | 20% | −20% |
| Net Profit | 94 | 122 | 101 | 80 | 89.42 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 | 187 |
| EPS (₹) | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 | — |
Sep 2026: from the results filed on 26 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| Expenses | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 2,009 | 2,092 |
| Operating Profit | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,120 | 1,138 |
| OPM % | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% | 35% |
| Other Income | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | −9 | −9 |
| Interest | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 | 191 |
| Depreciation | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 | 281 |
| PBT | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 638 | 657 |
| Tax % | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | −1% | — |
| Net Profit | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS (₹) | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.1 | 28.82 | 25.84 | 44.72 | 46.75 |
| Div. Payout % | 0% | 63% | 0% | 0% | 0% | 13% | 21% | 20% | 26% | 0% | 28% | 16% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,889 |
| Borrowings | 1 | 0 | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,359 |
| Other Liabilities | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,415 | 861 |
| Total Liabilities | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
| Fixed Assets | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,188 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 |
| Investments | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other Assets | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,307 | 1,702 |
| Total Assets | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | 538 |
| Investing | −92 | −44 | −184 | −590 | −5 | 123 | −323 | −320 | −975 | −1,828 | −78 | −369 |
| Financing | 0 | −84 | −24 | 363 | −221 | −335 | −82 | −45 | 688 | 1,380 | −881 | −314 |
| Net Cash Flow | −2 | 4 | −8 | 8 | −3 | 60 | −30 | 14 | 5 | 38 | 105 | −145 |
| Free Cash Flow | 77 | 108 | 150 | 210 | 186 | 125 | 350 | 258 | −550 | 357 | 910 | 241 |
| CFO/OP | 96 | 97 | 94 | 94 | 85 | 87 | 103 | 94 | 68 | 87 | 114 | 59 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 | 79 |
| Inventory Days | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 | 200 |
| Days Payable | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 | 151 |
| Cash Conversion Cycle | 97 | 102 | 84 | −40 | 28 | −12 | 30 | 44 | 70 | 48 | 59 | 129 |
| Working Capital Days | 15 | 9 | 23 | −13 | −17 | 59 | 64 | 75 | 50 | −296 | −49 | −71 |
| ROCE % | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% | 14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Eris Lifesciences insights
67 extracted metrics across FY11–FY27.
Documents
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT
- Q2 FY26 concall · Nov 2025Transcript PPT
- Q1 FY26 concall · Aug 2025Transcript PPT
- 8 May 2026
- 9 May 2025
- 5 May 2025
- 28 May 2024
- 15 Mar 2024
- General announcements 29 Oct 2026
- General announcements 26 Oct 2026
Frequently Asked Questions about Eris Lifesciences
What does ERIS Lifesciences Ltd do?
Where is ERIS Lifesciences Ltd (ERIS) listed?
Which sector does ERIS Lifesciences Ltd belong to?
What is the PE ratio of ERIS Lifesciences Ltd?
What is the 52-week high and low of ERIS Lifesciences Ltd?
Does ERIS Lifesciences Ltd pay dividends?
What is the Return on Equity (ROE) of ERIS Lifesciences Ltd?
Company Information
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ERIS.md for ERIS Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.